Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C16H16ClN3O3S
Número CAS:
Peso molecular:
365.83
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlegrade
pharmaceutical primary standard
API family
indapamide
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CC1Cc2ccccc2N1NC(=O)c3ccc(Cl)c(c3)S(N)(=O)=O
InChI
1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
InChI key
NDDAHWYSQHTHNT-UHFFFAOYSA-N
Gene Information
human ... SLC12A3(6559)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Indapamide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Indapamide Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Lact. - Repr. 2
Clase de almacenamiento
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Sheng Kang et al.
Clinical therapeutics, 26(2), 257-270 (2004-03-25)
A low-dose combination of perindopril and indapamide may effectively reduce blood pressure (BP) in hypertensive patients, but some factors related to study design might have contributed to the between-group differences in the rate of reduction of BP observed in some
G Damien et al.
Clinical pharmacokinetics, 37 Suppl 1, 13-19 (1999-09-24)
In accordance with international guidelines recommending the use of low doses of antihypertensive agents, a new formulation of indapamide--indapamide sustained release (SR)--has been developed. Indapamide has been used worldwide for many years as an immediate release (IR) formulation at a
Peter W de Leeuw
Expert opinion on pharmacotherapy, 12(11), 1827-1833 (2011-06-10)
Hypertension is an important risk factor for cardiovascular complications and the need to treat this condition has been well established. Despite the availability of many antihypertensive drugs, it is often necessary to combine several of these drugs. The compound perindopril/indapamide